Combining VEGF receptor inhibitors and angiotensin-(1–7) to target renal cell carcinoma

Resistance to tyrosine kinase inhibitors of the vascular endothelial growth factor receptor inevitably develops in most patients with metastatic kidney cancer. Our recent findings demonstrate that addition of angiotensin-(1-7) peptide can be a potential therapy that delays such resistance.

Detalles Bibliográficos
Autores principales: Walther, Thomas, Khanna, Prateek, Bhatt, Rupal S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489949/
https://www.ncbi.nlm.nih.gov/pubmed/34616864
http://dx.doi.org/10.1080/23723556.2021.1918529
_version_ 1784578426884063232
author Walther, Thomas
Khanna, Prateek
Bhatt, Rupal S.
author_facet Walther, Thomas
Khanna, Prateek
Bhatt, Rupal S.
author_sort Walther, Thomas
collection PubMed
description Resistance to tyrosine kinase inhibitors of the vascular endothelial growth factor receptor inevitably develops in most patients with metastatic kidney cancer. Our recent findings demonstrate that addition of angiotensin-(1-7) peptide can be a potential therapy that delays such resistance.
format Online
Article
Text
id pubmed-8489949
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-84899492021-10-05 Combining VEGF receptor inhibitors and angiotensin-(1–7) to target renal cell carcinoma Walther, Thomas Khanna, Prateek Bhatt, Rupal S. Mol Cell Oncol Commentary Resistance to tyrosine kinase inhibitors of the vascular endothelial growth factor receptor inevitably develops in most patients with metastatic kidney cancer. Our recent findings demonstrate that addition of angiotensin-(1-7) peptide can be a potential therapy that delays such resistance. Taylor & Francis 2021-06-12 /pmc/articles/PMC8489949/ /pubmed/34616864 http://dx.doi.org/10.1080/23723556.2021.1918529 Text en © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Commentary
Walther, Thomas
Khanna, Prateek
Bhatt, Rupal S.
Combining VEGF receptor inhibitors and angiotensin-(1–7) to target renal cell carcinoma
title Combining VEGF receptor inhibitors and angiotensin-(1–7) to target renal cell carcinoma
title_full Combining VEGF receptor inhibitors and angiotensin-(1–7) to target renal cell carcinoma
title_fullStr Combining VEGF receptor inhibitors and angiotensin-(1–7) to target renal cell carcinoma
title_full_unstemmed Combining VEGF receptor inhibitors and angiotensin-(1–7) to target renal cell carcinoma
title_short Combining VEGF receptor inhibitors and angiotensin-(1–7) to target renal cell carcinoma
title_sort combining vegf receptor inhibitors and angiotensin-(1–7) to target renal cell carcinoma
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489949/
https://www.ncbi.nlm.nih.gov/pubmed/34616864
http://dx.doi.org/10.1080/23723556.2021.1918529
work_keys_str_mv AT waltherthomas combiningvegfreceptorinhibitorsandangiotensin17totargetrenalcellcarcinoma
AT khannaprateek combiningvegfreceptorinhibitorsandangiotensin17totargetrenalcellcarcinoma
AT bhattrupals combiningvegfreceptorinhibitorsandangiotensin17totargetrenalcellcarcinoma

Ejemplares similares